Stockscreener 앱 받기
8.85
0.68%
0.06
시간 외 거래:
8.85
전일 마감가:
$8.79
열려 있는:
$8.8
하루 거래량:
13,371
Relative Volume:
0.02
시가총액:
$6.76M
수익:
$202.00K
순이익/손실:
$-28.96M
주가수익비율:
-14.75
EPS:
-0.6
순현금흐름:
$-21.85M
1주 성능:
-4.53%
1개월 성능:
+9,226%
6개월 성능:
+4,388%
1년 성능:
+2,112%
1일 변동 폭
$8.30
$9.1007
1주일 범위
$8.30
$9.66
52주 변동 폭
$0.0633
$14.93
AIM ImmunoTech Inc Stock (AIM) Company Profile
명칭
AIM ImmunoTech Inc
전화
352 448 7797
주소
2117 SW Highway 484, Ocala, FL
AIM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
8.85 | 7.08M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.81 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.92 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
279.16 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
AIM ImmunoTech Inc 주식(AIM)의 최신 뉴스
Omega Therapeutics (NASDAQ:OMGA) versus AIM ImmunoTech (NYSE:AIM) Head-To-Head Review - Defense World
AIM ImmunoTech Announces Recent Presentation on the - GlobeNewswire
AIM ImmunoTech (NYSE:AIM) Shares Gap Up – Here’s What Happened - Defense World
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements - The Manila Times
AIM ImmunoTech's Compliance Crossroads: Balancing Risk and Reward in a High-Stakes Gamble - AInvest
AIM ImmunoTech resumes trading on NYSE American By Investing.com - Investing.com India
AIM ImmunoTech resumes trading on NYSE American - Investing.com
AIM ImmunoTech Resumes Trading on NYSE American - The Manila Times
AIM ImmunoTech Inc. Common Stock Resumes Trading on NYSE American - Nasdaq
Aim Immunotech CEO Thomas Equels acquires $823 in common stock By Investing.com - Investing.com India
Aim Immunotech CEO Thomas Equels acquires $823 in common stock - Investing.com
AIM ImmunoTech granted U.S. patent for Ampligen - MSN
Aim Immunotech CEO Thomas Equels acquires shares worth $896 By Investing.com - Investing.com Nigeria
Aim Immunotech CEO Thomas Equels acquires shares worth $896 - Investing.com Australia
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension - GlobeNewswire
AIM ImmunoTech Regains NYSE Compliance, Stock Reinstated - TipRanks
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen® - The Manila Times
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, ... - Bluefield Daily Telegraph
New Patent Grant Extends Ampligen Manufacturing Protection for 18 Years: Major Win for Cancer and COVID Drug - Stock Titan
NYSE American Lifts AIM ImmunoTech Trading Ban After Stock Price Recovery - Stock Titan
AIM ImmunoTech Inc. Announces 1-for-100 Reverse Stock Split Effective June 12, 2025 - Nasdaq
Aim Immunotech Announces 1-For-100 Reverse Stock Split - MarketScreener
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split - GlobeNewswire
AIM ImmunoTech Sets Massive 1:100 Reverse Split to Save NYSE American Listing - Stock Titan
AIM ImmunoTech Reports Q1 2025 Financial Results - TipRanks
AIM ImmunoTech Announces the Presentation of Ampligen - GlobeNewswire
AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists - Stock Titan
AIM ImmunoTech Announces Launch of CEO Corner Platform - Investegate
AIM ImmunoTech’s Drug Ampligen to Be Tested by Japan’s National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19 - ACCESS Newswire
AIM ImmunoTech’s CEO to Present at Maxim’s Infectious Disease Virtual Conference - ACCESS Newswire
AIM ImmunoTech’s Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome - ACCESS Newswire
AIM ImmunoTech files to sell units, no amount given - MSN
AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
AIM ImmunoTech Inc. Decreases SARS-CoV-2 Infectious Viral Yields by 90% Using New In Vitro Model; Supports Further Testing of Ampligen as an Intranasal Prophylactic to Prevent COVID-19 - ACCESS Newswire
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 - The Globe and Mail
AIM ImmunoTech Inc. Names Ellen Lintal as New Chief Financial Officer - marketscreener.com
AIM ImmunoTech receives NYSE American notice of delisting and appeal - MSN
AIM ImmunoTech appoints Chemerow as an Independent Director - MSN
Aim ImmunoTech CEO Thomas K Equels buys $2,583 in common stock - Investing.com Canada
AIM ImmunoTech begins trading under new ticker AIMI - Investing.com Australia
AIM ImmunoTech begins trading under new ticker AIMI By Investing.com - Investing.com India
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market - The Manila Times
AIM ImmunoTech Inc (AIM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.40%
2.49%
자본화:
|
볼륨(24시간):